{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:53:08Z","timestamp":1777909988126,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Bilastine is a second-generation antihistamine that has been shown to be effective for treatment of allergic conjunctivitis. The objective of this study was to evaluate the pharmacokinetics (PKs) and biodistribution of 0.6% bilastine preservative-free eye drops.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Bilastine was quantified in the conjunctiva, cornea, aqueous humor, vitreous humor, iris\/ciliary body, retina\/choroid, crystalline lens, and plasma, following a single topical administration to male Dutch-belted rabbits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Concentrations of bilastine were highest in the conjunctiva [C\n                      <jats:sub>max<\/jats:sub>\n                      : 2,545.04\u2009ng\/g, at 6\u2009h postadministration; area under the concentration\u2013time curve (AUC\n                      <jats:sub>t<\/jats:sub>\n                      ): 11,382.40\u2009ng\u00b7h\/g] and cornea (C\n                      <jats:sub>max<\/jats:sub>\n                      : 609.11\u2009ng\/g, at 1\u2009h postadministration; AUC\n                      <jats:sub>t<\/jats:sub>\n                      : 1,993.88\u2009ng\u00b7h\/g), followed by the iris\/ciliary body, retina\/choroid, aqueous humor, plasma, vitreous humor, and crystalline lens. Quantifiable bilastine concentrations were observed up to 24\u2009h after instillation in the conjunctiva (388.45\u2009ng\/g), cornea (28.68\u2009ng\/g), iris\/ciliary body (12.42\u2009ng\/g), retina\/choroid (1.91\u2009ng\/g), and crystalline lens (0.12\u2009ng\/g). In plasma, aqueous humor, and vitreous humor, bilastine was detected up to 12\u2009h postadministration (0.18\u2009ng\/mL, 0.40\u2009ng\/mL, and 0.32\u2009ng\/g, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PKs and biodistribution of 0.6% bilastine eye drops in rabbits revealed a marked preferential distribution in the conjunctiva (target tissue), with sustained levels up to 24\u2009h. These findings are consistent with clinical efficacy trials supporting once-daily administration of topical bilastine for treatment of allergic conjunctivitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2022.0024","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T12:47:05Z","timestamp":1666356425000},"page":"617-625","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24\u2009h Postadministration"],"prefix":"10.1177","volume":"38","author":[{"given":"In\u00e9s","family":"Torrens","sequence":"first","affiliation":[{"name":"Research, Development and Innovation Department (R&amp;D+i Department), Faes Farma, Bizkaia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Ganza","sequence":"additional","affiliation":[{"name":"Research, Development and Innovation Department (R&amp;D+i Department), Faes Farma, Bizkaia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Research, Development and Innovation Department (R&amp;D+i Department), Faes Farma, Bizkaia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonzalo","sequence":"additional","affiliation":[{"name":"Research, Development and Innovation Department (R&amp;D+i Department), Faes Farma, Bizkaia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Zazpe","sequence":"additional","affiliation":[{"name":"Research, Development and Innovation Department (R&amp;D+i Department), Faes Farma, Bizkaia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1998.0280s6008.x"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1484"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101043440106"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-012-0252-9"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e328364ec7a"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/1824-7288-39-18"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32834a9676"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03716.x"},{"key":"e_1_3_6_10_2","first-page":"149","article-title":"Updates in the treatment of ocular allergies","volume":"3","author":"Kari O","year":"2010","unstructured":"Kari O, , Saari KM. Updates in the treatment of ocular allergies. J Asthma Allergy, 2010; 3:149\u2013158; doi:10.2147\/JAA.S13705","journal-title":"J Asthma Allergy"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.13786"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.5497\/wjp.v2.i2.47"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0954-7894.2002.01314.x"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.110832"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-015-0008-x"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2016.63942"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060525"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/11209310-000000000-00000"},{"key":"e_1_3_6_19_2","unstructured":"Clinical Trials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03231969; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03479307 [Last accessed: February 2022]."},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-0167-9"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-016-0339-2"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2012.103"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2015.08.023"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0042"},{"issue":"113","key":"e_1_3_6_25_2","first-page":"53878","article-title":"Use of rabbit eyes in pharmacokinetic studies of intraocular drugs","author":"Ahn SJ","year":"2016","unstructured":"Ahn SJ, , Hong HK, , Na YM, et al. Use of rabbit eyes in pharmacokinetic studies of intraocular drugs. J Vis Exp, 2016;(113):53878; doi: 10.3791\/53878","journal-title":"J Vis Exp"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0140"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9183-3"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-409X(95)00012-V"},{"issue":"4","key":"e_1_3_6_29_2","first-page":"584","article-title":"Importance of the noncorneal absorption route in topical ophthalmic drug delivery","volume":"26","author":"Ahmed I","year":"1985","unstructured":"Ahmed I, , Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci, 1985; 26(4):584\u2013587.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_6_30_2","doi-asserted-by":"crossref","unstructured":"Gukasyan H Kim KJ Lee V. The conjunctival barrier in ocular drug delivery. In: Ehrhardt C Kim KJ (eds.). Drug Absorption Studies. Biotechnology: Pharmaceutical Aspects Vol. VII. Springer: Boston MA 2008; pp. 307\u2013320. https:\/\/doi.org\/10.1007\/978-0-387-74901-3-13","DOI":"10.1007\/978-0-387-74901-3_13"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600760802"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-409X(95)00010-5"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.2174\/1872211308666140130093301"},{"key":"e_1_3_6_34_2","unstructured":"U.S. Food and Drug Administration. New Drug Application (NDA) 208694. Available from: https:\/\/www.fda.gov\/media\/105982\/download. [Last accessed: July 2022]."},{"key":"e_1_3_6_35_2","unstructured":"U.S. Food and Drug Administration. New Drug Application (NDA) 21\u2013127. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21127_Optivar.cfm [Last accessed: July 2022]."},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.154906"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.604029"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.052704"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600721108"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.12.009"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199529040-00002"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.09.011"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1006\/rtph.1998.1243"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2012.03.004"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2022.0024","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2022.0024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2022.0024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:45:09Z","timestamp":1777646709000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2022.0024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,11,1]]}},"alternative-id":["10.1089\/jop.2022.0024"],"URL":"https:\/\/doi.org\/10.1089\/jop.2022.0024","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}